Drug Profile
Elimusertib - Bayer
Alternative Names: BAY-1895344; BAY-1895344 HClLatest Information Update: 02 Jan 2024
Price :
$50
*
At a glance
- Originator Bayer
- Developer Bayer; National Cancer Institute (USA)
- Class Antineoplastics; Morpholines; Naphthyridines; Pyrazoles; Small molecules
- Mechanism of Action ATR protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
- Phase I Head and neck cancer; Lymphoma; Ovarian cancer
Most Recent Events
- 01 Dec 2023 Bayer and GlaxoSmithKline terminates a Phase-I clinical trials in Solid tumours and Ovarian cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater, Recurrent, Combination therapy) in USA (PO) due to no anticipated benefits from experimental combinations (NCT04267939) (EudraCT2018-003930-34)
- 11 Oct 2023 Bayer completes a Phase-I clinical trials in Lymphoma in US, Canada, China, Japan, Singapore, Switzerland, France and the UK (NCT03188965) (JapicCTI183998)(EudraCT2016-004484-39)
- 02 Jun 2023 Pharmacokinetics and adverse events data from a phase I/II trial in Solid tumours presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)